eligibility_summary
Eligible: Acute HIV, ART started ≤90 days, on INSTI (or DTG/3TC) ≥6 weeks, VL <50 for ≥1 year, CD4 ≥500, weight 50–150 kg, no >14‑day ART gaps, willing for ATI/restart and contraception if needed, HLA/leukapheresis done. Exclude: pregnancy/breastfeeding, prior bNAbs/LRA/Ad‑vectored or recent vax, severe allergy/anaphylaxis/coagulopathy, autoimmune/neurologic/skin, OIs/malignancy/TB, recent serious illness, multiclass resistance, ASCVD, advanced liver disease, immunomodulators, CAM.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Interventions and mechanisms: 1) Therapeutic conserved-mosaic T‑cell vaccines (ChAdOx1.tHIVconsv1/ChAdOx1.HIVconsv62 prime, MVA.tHIVconsv3/4 boosts)—viral‑vector vaccines expressing HIVconsvX antigens to drive broad HIV‑specific cellular immunity. 2) Vesatolimod (VES)—oral small‑molecule TLR7 agonist activating innate sensing (pDCs/B cells/monocytes), inducing type I IFN, potentially reversing latency and enhancing NK/CD8 effector function. 3) Broadly neutralizing antibodies: GS‑5423 (3BNC117‑LS/teropavimab, CD4 binding site) and GS‑2872 (10‑1074‑LS/zinlirvimab, V3‑glycan)—neutralize Env and mediate Fc effector functions (ADCC/ADCP). Targets: dendritic/APC priming, TLR7 pathway, NK cells, HIV‑specific CD8+ and CD4+ T cells, HIV‑1 Env (CD4bs, V3‑glycan), latently infected CD4+ T‑cell reservoir. Goal: achieve post‑ART control during ATI.